JSR's operating profit rose 121.6% to ¥42.0bn in the six months to September 2026, with electronic materials for advanced chips doing the heavy lifting. In the same half-year report, filed on 16 November, the company disclosed that its agreed sale of Crown Bioscience has been cancelled.
Chips carry the half
Revenue grew 27.8% to ¥265.1bn. Profit before tax reached ¥23.7bn, against ¥3.1bn a year earlier, and profit attributable to owners of the parent rose to ¥15.7bn from ¥3.4bn.
The digital solutions segment produced most of it: revenue of ¥152.3bn, up 29.6%, and operating profit of ¥35.8bn, up 62.7%. JSR attributes the gain to strong demand for advanced-semiconductor materials in Asian markets, and says AI-related demand in the chip market ran stronger than expected. Those explanations are the company's own.
Synthetic resins improved from a small base. Operating profit rose 368.9% to ¥3.5bn as JSR passed higher raw-material costs, which it links to rising crude prices amid Middle East tensions, into selling prices.
| Segment | Revenue | Revenue change | Operating profit |
|---|---|---|---|
| Digital solutions | ¥152.3bn | +29.6% | ¥35.8bn |
| Synthetic resins | ¥51.9bn | +13.7% | ¥3.5bn |
| Life sciences | ¥60.6bn | +48.8% | ¥3.7bn (from a ¥4.9bn loss) |
Life sciences: a swing with a lump sum in it
The life sciences segment moved from an operating loss of ¥4.9bn to a profit of ¥3.7bn on revenue of ¥60.6bn. JSR says the CDMO business, which makes biologic drugs under contract, booked revenue from past transactions with customers in one lump at KBI Biopharma, which lifted both revenue and profit. Cost control in its CRO business also helped. The report does not give the size of the lump sum.
Segment profits total ¥43.2bn, but consolidated operating profit is ¥42.0bn after ¥1.1bn of unallocated corporate costs. JSR describes life sciences as a non-core business and says it continues to consider all options for it.
The sale that did not close
JSR Life Sciences, LLC had agreed on 13 November 2025 to sell all shares in its subsidiary Crown Bioscience International to Miramar Lifesciences Limited, a group company of Hong Kong-listed Adicon Holdings. The parties agreed to terminate the contract effective 13 November 2026. JSR says the closing conditions were not expected to be met within the period originally assumed.
Crown Bioscience stays with JSR Life Sciences, and JSR says it will look for a new buyer. The effect on this fiscal year's consolidated results is, in JSR's words, under review, so the report puts no loss or gain on the cancelled deal. It also gives no price for the original sale.
The independent auditor's interim review report carries an emphasis-of-matter paragraph on the termination. The paragraph states that it does not affect the auditor's conclusion, which found nothing to suggest the interim statements were not fairly presented in all material respects. An interim review uses more limited procedures than a full audit.
Balance sheet
JSR repaid ¥56.1bn of long-term borrowings in the half and received ¥28.8bn from business transfers. Total liabilities fell to ¥659.3bn, and the equity ratio attributable to owners of the parent stood at 38.1%, against 34.8% at the end of March.
